Insulin-like Growth Factor Binding Proteins and Cellular Senescence Are Involved in the Progression of Non-Alcoholic Fatty Liver Disease and Fibrosis in a Mouse Model

• Published in: Medicina (Kaunas, Lithuania) Vol. 60; no. 3; p. 429
• Main Authors: Guzmán, Carolina, Bautista-Ubaldo, Miriam G., Campos-Espinosa, Adriana, Romero-Bello, Ivette I., Santana-Vargas, Ángel Daniel, Gutierrez-Reyes, Gabriela
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: Analysis; Animals; Binding proteins; Cellular Senescence; Choline - metabolism; Choline - pharmacology; Disease Models, Animal; Fatty liver; Fibrosis; Humans; Insulin resistance; Insulin-Like Growth Factor Binding Protein 1; insulin-like growth factor binding proteins; Insulin-like growth factors; Insulin-Like Peptides; Lipids; Liver; Liver cancer; Liver Cirrhosis - complications; liver fibrosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - complications; Protein binding; steatohepatitis; steatosis; Type 2 diabetes; United States > US; insulin-like growth factor binding proteins; steatohepatitis; liver fibrosis; cellular senescence; steatosis
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60030429

Background and Objectives: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent worldwide. It progresses from simple steatosis to non-alcoholic steatohepatitis (NASH). Fibrosis is often present during NAFLD progression; however, factors determining which subjects develop NASH or fibrosis are unclear. Insulin-like growth factor binding proteins (IGFBPs) are a family of secreted proteins involved in senescence and scarring, mainly synthetized in the liver. Here, we aimed to study the association of IGFBPs and their induced senescence with the progression of NAFLD and liver fibrosis. Materials and Methods: A total of 16-week-old male C57BL/6 mice weighing 23 ± 3 g were fed either methionine/choline-deficient (MCD) or control diet for 2, 8, or 12 weeks. Blood and liver samples were collected, and a histological assessment of NAFLD and fibrosis was performed. Fat contents were measured. Cellular senescence was evaluated in the liver. IGFBP levels were assessed in the liver and serum. Data were expressed as mean ± SD and analyzed by a one-way ANOVA followed by Tukey’s test. Lineal regression models were applied for NAFLD and fibrosis progression. p < 0.05 was considered significant. Results: IGFBP-1 and -2 were increased in serum during NAFLD. IGFBP-7 was significantly increased in the serum in NASH compared with the controls. Senescence increased in NAFLD. Serum and liver IGFBP-7 as well as SA-β-gal activity increased as fibrosis progressed. Both IGFBP-7 and cellular senescence were significantly higher during NAFLD and fibrosis in MCD-fed mice. Conclusions: IGFBP-1, -2, and -7, through their consequent senescence, have a role in the progression of NAFLD and its associated fibrosis, being a plausible determinant in the progression from steatosis to NASH.